Adverse drug interaction risks in genetically-defined subpopulations
Presenter: Maciej Czerwinski, Ph.D., Director of XenoTech Products R&D
Synopsis: An increased appreciation of the effects of genetic variability on the pharmacokinetic and pharmacodynamic properties of xenobiotics creates a need for specialized tools to evaluate new drugs from the pharmacogenomics perspective. Preclinical examination of drug metabolism with consideration of patient population diversity may reduce the risk of adverse effects upon first administration of a xenobiotic to humans and during further phases of drug testing and expansive use. An extensive polymorphism of drug metabolizing enzymes and drug transporters is well established. Human genetically-defined liver microsomes and most recently pooled cryopreserved hepatocytes constitute test systems for the pharmacogenetically-informed study of drug metabolism. Characterization of XenoTech Geneknown™ hepatocytes and criteria applied for creating genetically-defined pools of cells are presented as part of the discussion.
Key concepts discussed in this webinar include:
- Effects of drug metabolizing enzyme polymorphisms on drug disposition
- Safety concerns associated with developing one dose for diverse patient population
- Genetic basis for some of the polymorphisms of important drug metabolizing enzymes
- Selecting the best test system to study the effects of specific genetic variants on drug metabolism
- Donor selection for effective test pools
What topic would you like to hear about?
Our experts are constantly on the hunt for new and exciting topics to present on, and nothing helps us figure out what you want to hear more than requests and feedback! Use our form to submit your request so we can continue producing educational materials you look forward to
